Unknown

Dataset Information

0

Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse.

ABSTRACT:

SUBMITTER: Kent A 

PROVIDER: S-EPMC7362348 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse.

Kent Andrew A   Vasu Sumithira S   Schatz Derek D   Monson Natalie N   Devine Steven S   Smith Clayton C   Gutman Jonathan A JA   Pollyea Daniel A DA  

Blood advances 20200701 13

Similar Datasets

Unknown Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
| S-EPMC6221102 | biostudies-literature
Unknown A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients.
| S-EPMC7656915 | biostudies-literature
Unknown Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
| S-EPMC10883823 | biostudies-literature
Unknown Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naive settings.
| S-EPMC10122101 | biostudies-literature
Unknown Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT.
| S-EPMC11840129 | biostudies-literature
Unknown Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
| S-EPMC8120140 | biostudies-literature
Unknown Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.
| S-EPMC3306138 | biostudies-literature
Unknown Maintenance therapy for AML after allogeneic HCT.
| S-EPMC9397403 | biostudies-literature
Unknown Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.
| S-EPMC11880982 | biostudies-literature
Unknown Recurrent transcriptional responses in AML and MDS patients treated with decitabine.
| S-EPMC9833843 | biostudies-literature